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ABSTRACT
A group of 41 peptides, each 24 amino acids long and overlapping with each other by 12 residues spanning the
total gag open reading frame (orf) of HIV-1 (HTLV-IIIBH 10 isolate) were synthesized using Fmoc chemistry.
The purified compounds were used in ELISA assays and tested for antibody reactivities in sera of human
HIV-1-infected and noninfected individuals. Sera of HIV humans showed reactivity against four defined
regions, two in pl7, one in p24, and one in pl5. The values of these reactivities were elevated especially in serum
samples of HIV individuals showing cross-reaction with gag proteins on Western blot. Amino acid sequence
comparison of HIV-1 gag proteins with those of human endogenous retroviruses (ERV K10, ERV 3) revealed
significant similarities predominantly in the domains showing elevated antibody cross-reactions. The majority
of sera from HIV-1+ individuals showed strong reactivities to the cross-reactive regions and to various other
peptide sequences, a sequential epitope recognized by all HIV-1+ sera could, however, not be identified. The
results suggest that human individuals may have immune reactions to endogenous retroviral protein sequences,
which are enhanced by infections with HIV-1. Specific antibodies to HIV-1 gag proteins are probably mainly
directed to tertiary structure defined epitopes formed by particle formation of the p24 monomers to the
nucleocapsid.
INTRODUCTION
The gag gene products of human immunodeficiency virustype 1 (HIV-1), the causative agent of AIDS, are synthe-
sized as a polyprotein precursor, p55, which is cleaved during
particle maturation. The resulting products are pl7, the matrix
protein which is anchored into the viral or infected cell mem-
brane by N-terminal myristic acid modification, p24 forming the
nucleocapsid and p 15, which is further processed into p9 and p6
and shows association with the viral RNA.'~4 Antibodies
directed against gag gene products appear early in HI V infection
and are reported to decline with progression of the disease due to
increasing antigenemia of p24, a phenomenon which may be
used as prognostic marker for alteration of the patient's clinical
status.510 Since amino acid sequences encoded by the gag
genes are highly conserved in various HIV-1 isolates' ' and also
show a high degree of homology with HIV-2, antibodies
directed especially to p24 may serve as a preferential diagnostic
marker as well for early diagnosis as in follow-up studies of the
infected patients during antiviral treatment. Tests using viral or
recombinant p24 antigen on Western blots are, however, ham-
pered by a significant degree of antibody-cross-reactions present
in sera of not-infected human individuals. An enzyme-linked
immunosorbent assay (ELISA) based on synthetic peptide anti-
gens, where only conserved predominantly and specifically
reacting compounds may be used should be able to avoid those
effects representing an optimal test system.
Furthermore, due to their particle-forming capacity,1213 re-
combinant gag products may serve as potential vaccine candi-
date, which allow the inclusion of additional epitopes from other
HIV-encoded proteins. A precondition for those developments
is the exact immunological characterization of the individual
domains present in gag-derived amino acid sequences. For this
reason we synthesized 41 peptides spanning the whole gag
polyprotein precursor, each about 24 residues in length overlap-
ping with each other by 12 amino acids.
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The purified and characterized compounds were used in
ELISA tests and assayed for reactivities with sera from HIV-1
~
humans, partly showing anti-p24 cross-reactions on Western
blots and HIV-1 + serum samples. The results are presented in
this article.
MATERIAL AND METHODS
Peptide synthesis
Peptide synthesis was done using a 9050 PepSynthesizer
(Milligen, Eschborn, FRG) using Fmoc (9-fluorenylmethyloxy-
carbonyl)-protected amino acids.14 The first residue was cou-
pled to polystyrene beads grafted with polyoxyethylene (Tenta-
Gel, Rapp-Polymere, Tübingen, FRG). Double couple cycles
were used at positions of the amino acid chain for the residues
following proline or glycine and when equal or similar amino
acid residues were clustered, in order to avoid incomplete
coupling reactions. f-Butyl (Ser, Thr, Tyr), r-butylester (Asp,
Glu), trityl (Cys, His, Gin, Asn), i-butyloxycarbonyl (Lys), and
4-methoxy-2,3,6-trimethylbenzenesulfonyl (Arg) groups were
used for side chain protection. Fmoc-protected amino acids were
converted to hydroxybenzotriazol-activated esters with 1.5
mmol hydroxybenzotriazol and 1.2 mmol of diisopropylcarbo-
diimide per mmol of amino acid directly prior to the coupling
procedure. The subsequent coupling reaction was performed in
yV.yV'-dimethylformamide, coupling times of 10 minutes were
used. Fmoc groups were removed by 20% piperidine, the
completeness of this reaction was monitored by fluorometric
measurement (all amino acids were purchased from Bachern
AG, Heidelberg, Germany, solvents were from Merck AG,
Darmstadt, Germany, chemicals from Aldrich, Steinheim, Ger-
many). After synthesis, side-chain-protecting groups were re-
moved by 4 h treatment in 50% trifluoroacetic acid in dichlo-
romethane or, when Arg-residues were present in the peptide
sequence, in 100% trifluoroacetic acid over night. Routine
addition of 3% anisol and 3% phenol as scavengers, and 5%
2-mercaptoethanol was used in cases where Arg and Trp resi-
dues were combined in the peptide's sequence. Solvents were
evaporated, the peptide suspended in 1-2 ml acetic acid and
precipitated in an excess of ice-cold i-butylethylether, washed
several times, and suspended in water. The peptide was lyo-
philized and purified by reverse-phase high-performance liquid
chromatography (HPLC) using a C2/C18 copolymer column
(PepS, Pharmacia, Freiburg, Germany) and a gradient of0-70%
acetonitrile in 0.1% trifluoroacetic acid. The peptide-containing
fractions were lyophilized and characterized by amino acid
sequencing (Applied Biosystems, Weiterstadt, Germany).
ELISA tests
Sera were selected according to their capacity to recognize
viral or recombinant gag proteins on Western blots.15 All sera
were used in a dilution of 1:100 in phosphate-buffered saline
(PBS), exceptions are indicated. Aliquots of 400 ng purified,
characterized peptide per well were maintained overnight in 0.2
M sodium carbonate buffer, pH 9.5, in 96 well microtiter plates
(Maxisorb, Nunc GmbH, Mainz, Germany). Free protein bind-
ing sites were saturated by 2 h incubation with gel solution (5
mg/ml, Sigma Chemicals, München, Germany). Before and
after the addition of the serum dilutions the plates were washed
several times with PBS/0.5% Tween-20. After incubation with
human sera, plates were washed with PBS/0.5% Tween-20 and
0.9% NaCl. Rabbit anti-human IgG (Dako, Hamburg, Ger-
many) was added in a dilution of 1:1000 in PBS. Staining was
carried out in 0.1 M phosphate buffer, pH 6.0, containing 1
mg/ml o-phenylendiamine and 0.1% H202 for 10 minutes; the
reaction was stopped with 1 M H2S04 and the optical density
was determined at 492 nm.
All sera were tested in double assays. For determination of
specific reactivities, the mean values of reaction of second
antibodies to the individual peptides without prior incubation
with human sera were subtracted from the mean values obtained
for the individual serum samples.
Competition assay
In the competition assay for p24, the antibody concentration
of HIV-1+ asymptomatic individuals was estimated by titration
on Western blots. The serum concentration with the band of p24
(or p55) still visible on Western blots was used in the following
assays. Western blot strips were prepared with HIV virus
propagated on H9 cells and lysed in sodium dodecyl sulfate(SDS) solution. In the competition assays the serum was incu-
bated without peptide for controls, with pools of pl7-derived
peptides (peptides 1-11), pl5-derived peptides (peptides 30-
41), and p24 (peptides 12-29). For each assay 4 u,g of each
peptide was used. After staining, densidometric evaluation of
the Western blots was done (Elscript 400; Hirschmann, Unterh-
aching, Germany).
For the ELISA competition assay, first the optimal concentra-
tion of the recombinant p24 protein was estimated by titration.
The recombinant protein (Mikrogen GmbH, Munich, FRG)
comprises the whole sequence of p24, including 12 aa of pl7 at
the N-terminal part and 74 aa of pi5 at the C-terminus. The
proteins were coated at 20 ng/well and incubated with serum
dilutions from 1:100 to 1:1600. The sera were preincubated with
pooled peptides (peptides 11-35, 100 p,g/assay), which spanned
the whole sequence of recombinant protein p24.
RESULTS
Selected peptides
Forty-one peptides spanning the gag polyprotein precursor
molecule (isolate HTLV-III/BH10;1) were synthesized. For
length, peptides of 24 residues were selected, since these are
able to form secondary structural motives and thus should allow
not only the detection of antibodies directed to sequential
epitopes but also of those directed to antigenic domains defined
by structural properties to form a-helical, ß-pleated sheet or
ß-turn protein regions. Occasionally peptides of 22 or 23
(peptides 1, 14, 15, 17) or 25 residues (peptides 27 and 30) were
synthesized. This averted difficulties during synthesis and al-
lowed us to obtain peptides with termini at the cleavage positions
for pl7/p24 and p24/pl5 identical to those obtained by the
procession of the polyprotein to the viral products pi 7, p24, and
pl5 in vivo. Each peptide had an overlap of 12 (or in some cases
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—
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O.D. m
pl7- p24
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- g -> <- 11 ->K-
-><- 10 -><:- 12
-
151 TLNAWVKWE EKAFSPEVIP MFSALSEGAT PQDLNTMLNT VGGHQAAMQM
-
13 -> <- 15 -x-
201 LKETINEEAA EWDRVHPVHA GPIAPGQMRE PRGSDIAGTT STLQEQIGWM
—
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-><- 18 -><- 20
-
251 TNNPPIPVGE IYKRWIILGL NKIVRMYSPT SILDIRQGPK EPFRDYVDRF
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301 YKTLRAEQAS QEVKNWMTET LLVQNANPDC KTILKALGPA ATLEEMMTAC
-><- 27 -><-
<- 26 -><- 28 ->
p24  pl5
351 QGVGGPGHKA RVLAEAMSQV TNTATIMMQR GNFRNQRKMV KCFNCGKEGH
29 -><- 31 -><-
<- 3Q -,,<- 32 ->
401 TARNCRAPRK KGCWKCGKEG HQMKDCTERQ ANFLGKIWPS YKGRPGNFLQ
33 -><- 35 -,<-
<- 34 -,<- 36 ->
451 SRPEPTAPPF LQSRPEPTAP PEESFRSGVE TTTPPQKQEP IDKELYPLTS
37 -><- 3g -><-
<- 38 -><- 40 ->
pl5
501 LRSLFGNDPS SQ
41
->
FIG. 1. Amino acid sequence of HIV-1 gag proteins (isolate
HIV-1/BH10;1) and location of the synthesized peptides. Loca-
tions ofprotease cleavage sites for processing of the precursor to
pi7, p24, and p!5 are indicated.
11 or 13) residues with the neighboring ones. Sequence and
location of the peptides on the gag proteins is shown in Figure 1.
Reactivity of HIV-1+ sera
In order to test antibody reactivity to gag-derived peptides,
sera of HIV+ individuals were selected which showed a clear
positive recognition of HIV-1 gag proteins on Western blot.
Serum dilutions of 1:100 were used in order to avoid high
background values due to unspecific binding to artificial struc-
tures. In general, reactivities of individual sera, when tested on
gag-derived peptides, were relatively low showing values for
optical density between 0.5 and 1.5. Higher reaction values
were seen only occasionally and preferentially with peptides
2-3, 9-11, 24, and 31-34 representing the protein regions of
amino acids 12-46, 97-145, 277-300, and 364-424 of the
polyprotein, respectively. Further positive reactivities to other
peptide antigens were observed in individual sera; these, how-
ever, could not be correlated with defined gag region (Fig. 2;
Table 1). All sera showed positive and high reactions with a
V3/gpl20-derived consensus peptide16 which was used as pos-
itive control. To exclude influences by different binding capac-
ity of the individual peptides to polystyrene plates, various
peptide concentrations (100, 200, 400, and 800 ng, 1 p.g) and
serum dilutions (1:10-1:400) were used, which did not lead to a
significant and specific enhancement of reactivity; also, differ-
ent coupling conditions on various ELISA plate systems had no
positive influence according to serum reactivity. Since all
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FIG. 2. Presentation and comparison of antibody reaction
values to the synthesized gag-derived peptides in ELISA-
assays. Values of 3 HIV-1 negative (A), 3 HIV-1~ cross-
reactive (B) and 4 HIV-1+ sera (C) are shown.
peptides showed positive signals on Western blot we concluded
that due to particle formation of p55 and p24, a process which is
thought to be associated with major changes of the monomeric
protein's structure, specific antibodies to gag proteins in HIV-
1-infected individuals are directed mainly to structural motives.
To test this assumption, we preincubated sera with peptide
mixtures and determined the remaining reactivity to p55/p24 on
Western blot and in ELISA assays using purified recombinant
p24 as antigen. In none of the tests, any reduction of anti-gag
reactivity could be observed (data not shown).
Reactivity ofHIV-f sera
When HIV sera were tested on the individual peptides
considerable reactivity with values for optical density up to 0.5
was observed in some serum samples despite the fact that all
those sera showed negative reactivity to gag products on West-
ern blot and in immunofluorescence (Fig. 2; Table 1). The
peptides, which showed such positive reactivity were identical
to those preferentially recognized by HIV-1 positive sera. In
addition, weak reactivities were identified to peptides 6 and 7 (aa
60-95), a region where HIV-1 positive sera were rather inactive.
Differences were only observed by quantitative means, the
HIV-1 positive sera showing clearly elevated values. Those
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Table 1. Reaction Values of Optical Density with HIV-1 gag Derived Peptides
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
HIV non-cross-reactive
14 sera tested
HIV cross-reactive
17 sera tested
HIV+
48 sera tested
Significant Significant Significant
Peptides Weak Middle High reaction % Weak Middle High reaction % Weak Middle High reaction %
2
4
7
2
5
21
5
7
36
36
10
7
1
2
4
4
2
7
4
6
3
2
4
3
3
4
5
4
1
4
2
3
4
2
2
2
1 1
2 1
2
—
4
—
6
41
6
6
18
29
18
24
12
12
6
12
12
18
12
24
6
12
47
35
64
6
35
6
6
6
24
12
21
4
1
9
8
4
6
9
12
17
5
4
13
6
2
8
5
1
1
2
20
9
14
5
18
2
1
1
5
2
2
—
5
22
12
1
17
66
14
4
2
2
21
2
14
2
4
4
4
2
10
12
2
2
4
55
65
56
12
57
6
4
2
16
6
Weak reaction: O.D. values 0.25-0.5; middle reaction: O.D. values 0.5-1.0; high reaction: O.D. values >1.0. Percentage of
significant reactions for the respective sera groups are indicated and represent sera with high and middle reactivity.
reactivities could not be reduced by other methods for adsorption
of peptide-free polystyrene plate surface with BSA (bovine
serum albumin), milk powder, or gelatine. In addition, different
procedures for washing after antibody exposition with high salt
or different detergents had no effect and the observed reactivities
were thus thought to be specific. HIV-1- sera derived from
children at the ages of 4 to 5 years were almost unreactive.
The positive antibody reactions to protein regions aa 12-46,
97-145, 277-300, 364-424 were enhanced when sera derived
from healthy HIV-negative persons were used for testing, which
showed positive reaction with gag products on Western blots.
These sera showed values similar to those observed with
HIV-1+ sera, especially for the peptides mentioned above.
Occasionally, additional peptides were recognized; in some
cases reactivities to one or two of the cross-reactive peptides
were relatively low. Since sera of HIV~ individuals showed
occasionally reactivities to gag-derived peptides similar to those
of HIV+ patients it was not possible to define a specific cut-off
value for the individual antigenic domains. Thus no peptide
could be identified to react specifically with the majority of
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Table 2. Number of Identical and Similar Amino Acid Residues in the Individual HIV-1 gag-DERivED Peptides
with Respect to Human Endogeneous Retrovirus Sequences ERV K10 and ERV 3
Peptides
herv klO herv 3
Identical Similar Identical
Amount % Amount Amount
Similar
Amount %
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
7
9
7
4
6
7
6
6
7
8
9
10
8
6
2
4
5
3
4
7
9
7
8
11
8
4
9
10
12
10
5
9
10
4
6
8
4
3
5
4
2
31
38
29
16
25
29
25
25
29
33
38
42
33
25
8
16
21
12
16
29
38
29
33
45
33
16
38
42
50
42
21
38
42
16
25
33
16
12
21
16
8
10
11
10
9
9
12
12
13
14
9
6
4
7
9
7
7
10
10
7
10
13
14
15
13
8
11
13
6
7
8
5
4
5
4
2
45
45
33
25
33
42
38
38
50
50
54
58
38
25
16
29
38
29
29
42
42
29
42
75
50
33
54
58
62
54
33
45
54
25
29
33
21
16
21
16
8
9
10
5
6
10
7
18
12
29
29
29
38
42
21
25
42
29
5
7
12
11
12
11
6
9
14
10
23
29
50
45
33
50
45
25
38
58
42
serum samples derived from HIV-infected persons: for regions
with high reactivities high cross-reactions are also observed; spe-
cifically, reacting peptides in individual samples could not be
correlated with a major antigenic domain, (Table 1, Fig. 2).
Significant specific reaction values were estimated for reactivities
showing values for optical density higher than 0.5 after correction
for second antibody reactivities (see Material and Methods).
An amino acid sequence comparison of gag proteins, in dot
plot analysis, derived from human endogenous retrovirus se-
quences (human ERV K10 and ERV3)1718 with HIV-I gag
proteins revealed stretches of homologous or similar sequences
especially in the regions, where highest values of cross-reactiv-
ity with HIV sera were observed (data not shown). COMPARE
and DOTPLOT or UWGCG computer program collections
were used with similar amino acid residues included in the
calculation.I9 Amino acid comparison of the cross-reactive gag
peptides with aligned gag sequences of ERV K10 and ERV3
revealed, that up to 40 and 70% of the residues of the individual
peptides were found to be identical or similar respectively (Table
2; Fig. 3).
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peptides
GAG HIV-1
GAG-1 hervklO
GAG herv3
VLSGG ELDRWEKI
JTXgKIKSKAS Y [í]s F
SR FK |GG¡FIYQFSTTD
NLSE VLSGGl G
K1ÇKYK
_
ST
WKHHTP @S
Mycopl.pneum.
E.coli DNA-polym.
E.coli Erythr.esterase
Pseudom.fluor.Pl GSLG@ TlLSGGl \&>ST UJfRC W Dg] [gjJYJr
AG
_IVLSCIY t|JgGADM1B BtfjiKKlfeEEM
LKHIVWASRE
MJLIKLFQ[yüjg fRBJAPSf
LNSTAGA HE LERFS
B
peptides
GAG HIV-1
GAG-1 hervklO
S.ceriv.pherom.rec.
s.ceriv.Leu3 prot.
Rhinov. IB
Strept.pyog.M5
Zymo.mob.GAPDH
HPV-8 E4 prot.
TK EALDK
_IEE EQNKSKKKAQQAAADTG HSSQVSQ NYPI V QNI
svstgPGScqipctg 0 TPQ<igsQ< etesi{jjceyj9íe Bvmaosi^vdy:
Pi PRK SBÑKSKKfrL FtÄfJl[FtritlKJK gEE EQIEIV
K EALDKYGVDLPMITFl
W EALD
I VDLPMIT
m YÜL IJtJHDIlE_gIÍL¡ «IglNE_/LK ^AAADTGl DMTGH
_
GSLLLKWEDÜFgLL IV QNI QCfclLE
c
peptide
GAG HIV-1
GAG-2 hervklO
YSPTSILD IROGPKEPFRDYVDRFGËÎcPSFNTVlRÛGjsSËaïPSff^SL
D
peptides
GAG HIV-1
GAG-2 hervklO
GAG herv3
Rhinovirus 14
VZV DNA-bindind pr. AL
HSV DNA-binding pr. AL
HSV DNA-polymerase
E.coli M-agglutinin.
32
AEAMSQV T NTA TIMMQ RGNFRNQR KMVKCFNCGKEGHTAR NCRAPRKKGCQIMLWQAI [TjGWLGGÍqMrI #) G G ¡KClYlÑCGbliGHtKK E3>VL1©NIhiSê5<pay ¡gs FrfcfrMQl pgpsTY@;TGRHs |g
mNKIATliVIPYI
HG VF EG
HG VFA GQSVEG
NFRtfcF
NFRNQfr
QF
QP
ÖSkPFS ^DRHLOfcRAPubtgpc|ghtâ^yl
FIG. 3. Amino acid comparison of crossreactive regions. Equal amino acid residues are framed. HIV gag proteins are aligned with
gag-1 and gag-2 proteins of human ERV K10 and human ERV 2 enogenous retrovirus sequences.28'29 In addition, local similarities
to bacterial and viral proteins of various origin are shown. (A) cross-reactive region 1 (aa 12-46, peptides 2, 3); (B) cross-reactive
region 2 (aa 97-146, peptides 8, 9, 10); (C) cross-reactive region 3 (aa 277-300, peptide 24); (D) cross-reactive region 4 (aa
364-424, peptides 31, 32, 33, 34).
DISCUSSION
Testing HIV+ human sera for antibody reactivity with puri-
fied peptides derived from gag-specific protein sequences in
order to define antigenic regions revealed a highly problematic
picture: Consistent reactivity was observed to protein regions,
which were recognized positively also by HIV~ sera, reactions
to other peptides were highly diverse in the individual serum
samples. This leads to the conclusion, that a sequential epitope is
not present in gag proteins of HIV and the majority of specific
antibodies is directed to structural domains on p24/p55 formed
by protein interaction of the polyprotein precursor molecules
leading to particle formation. This is confirmed by the observa-
tion, that preincubation with peptide mixtures did not reduce
reactions to p24 or p55. Other authors used different approaches
to define antigenic domains in the p24-region of the gag
polyprotein: Monoclonal antibodies to detergent-treated viral
lysates or purified gag proteins were produced and were mapped
to defined amino acid sequences using short overlapping pep-
tides,20~22 recombinant bacterial gag fragments,23'24 or viral
lysate25 as antigen. These experiments led to the definition of
antigenic epitopes in gag products, which, however show a
rather broad variety in the individual papers, probably depend-
ing on the nature of the antigen used for immunization. Only one
region (amino acids 210-225) is recognized rather constantly.
The situation tested in those cases is, however, different from
the in vivo infection in humans, since monomeric p24 not
present during virus infection and replication has been used as
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antigen. On those monomeric proteins antigenic regions which
are secluded on the viral nucleocapsid by protein interactions
may be exposed to the surface. Testing of the more natural
situation by the use of human sera showed a high diversity in
reaction when short peptides were used as antigens (9-
mers),21,22 which is similar to our finding where longer peptides
(24-mers) were used, which allow the identification of second-
ary structure motives in addition to sequential epitopes. Regions
recognized by mouse monoclonal antibodies also reacted with
some human sera, but did not show preferential recognition: this
finding may be explained by the highly diverse reactivities in the
individual human serum samples.
The fact, that HIV~ sera show cross-reactivities especially
with those protein regions that also show enhanced reactivities in
HIV-1+ serum samples implies that similar sequences have
already been exposed to the immune system prior to HIV-
infection. In other viral systems regions with similar amino acid
sequences or similar epitopes leading to cross-reaction have
been reported for cytomegalovirus.26 In patients with autoim-
mune diseases like Sjögren's syndrome,27'28 SLE and others
cross-reactivities to gag proteins of HIV or other retroviruses
were reported,29,30 which may contribute to positive recognition
of gag-derived peptides in individual sera.
Searching the protein sequences of NBRF and PIR banks
revealed stretches of homologous amino acids present in poly-
peptides of bacterial or viral agents predominantly present in the
regions responsible for high cross-reactivities described in this
paper (Fig. 3). Since two of those regions, the aminoterminal
part of pl7 and the amino acid residues 364-424 of pi5,
comprise consensus sites for NH2-terminal myristylation and
nucleic acid binding in form of a potential Zinc finger region
respectively, it has to be anticipated that sequentially and
structurally similar domains are present in proteins of various
infectious agents, which may contribute to the observed cross-
reactions.
Amino acid sequence comparison of gag 1 and gag 2 proteins
of human erv K10 and human erv 3 to HIV-1 gag revealed
stretches of homologous or similar sequences especially in the
region, where highest values of cross-reactivity with HIV-
negative sera was observed.
Endogenous retrovirus are widespread in mammalians and are
thought to make up at least 0.1 to 0.6% of the human DNA.31
This feature, that DNA of normal uninfected cells contains gene
sequences which are closely related to exogeneous infectious
retroviruses, is unique among animal and human viruses. Their
function is unknown, they possibly serve as a source of genetic
variation, a reservoir for recombination, or may contribute to the
origin of pathogenic retroviruses.32 For the Gibbon ape leuke-
mia viruses (GaLV) it could be shown that the DNA integrates
into human cells.33 Its sequence is indistinguishable from that of
the fragments derived from the simian endogenous retrovirus
SSAV (simian sarcoma-associated virus), where the gag and the
pol regions contain sequences which are highly conserved in
numerous retroviruses. GaLV is antigenically most closely
related to a new world monkey virus, SSAV and less to the
murine and feline C-type leukemia viruses.34 In a similar way,
antigenic relationship may be assumed between HIV and endog-
enous human retroviruses.
Only a few sequences present in human cellular DNA are
known and in analogy with murine and simian systems, a large
variety has to be assumed. All examples so far seem to be
replication defective; however, some show transcriptional activ-
ity in individual tissues as human placenta and cell lines derived
from human cancer or leukemia.35-37
The fact, that regions of HIV-1 gag products which exhibit
distinct similarities to known sequences of human endogeneous
retrovirus gag proteins show highest cross-reactivities in HIV~
sera point to the possibility, that those genes may be activated to
protein synthesis during periods of postnatal life and lead to the
production of antibodies or primed T-helper lymphocytes. This
hypothesis can be supported by the finding of antibody reactions
against capsid proteins of the simian viruses, SSAV and Mason
Pfizer monkey retroviruses in HIV p24 crossreactive sera.38 In
those cases, where activated endogeneous gag sequences are
similar to HIV gag proteins, infection with HIV may represent a
"booster"-like effect resulting in the proliferation of antibody-
producing B-cells, which can be stimulated by T-helper cells
already primed for similar epitopes. Due to intracellular degra-
dation of foreign antigen, and presentation of peptide sequences
in combination with HLA class 2 proteins primarily sequential
epitopes are recognized by those cross-reactions. Furthermore,
experiments to vaccinate macaques with inactivated simian
immunodeficiency virus (SIV) infected cells led to the discovery
that protection was obtained by antibodies against certain cell
components.39 The nature of cellular components that led to
protection in vivo is still unclear. Anti-gag cross-reactions,
possibly based on immune reaction to endogenous retrovirus
proteins, may contribute to the status of protection against SIV
infection in unvaccinated animals.
In cases, when endogenous retroviral sequences are activated
during embryonic stages of development, those sequences
should be recognized as "self proteins and immune reactivity
against those and homologous proteins is avoided by education
of premature T lymphocytes in the embryonic thymus.
Possibly both ways—activation of endogenous retrovirus
sequences in postnatal life leading to a primed immune system
with the production of specific antibodies, which may cross-
react with similar domains on one side or activation during
embryonic development as a result of clonal deletion of the
respective T cells—may contribute to the highly diverse and
complicated immune reaction found in humans to gag products
during HIV infection.
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